IFTEQAR SYED: Open Payments
NPI 1518963081 · PARIS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$448 in 32 payments from 5 companies in 2025. Trend: 2023 $379 · 2024 $306 · 2025 $448
Food & beverage: $448
| Company | Payments | Amount |
|---|---|---|
| Forte Bio-Pharma LLC | 13 | $196 |
| ABBVIE INC. | 15 | $173 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $21 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
Products named: PROLATE, UBRELVY, RELISTOR, Quviviq, QULIPTA, JOURNAVX, TANLOR.
Industry payments across TX — which companies pay providers there.
